Italia markets close in 16 minutes
  • Reuters

    UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer

    Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer. Last week, Vanda rejected contract manufacturer Future Pak's offer of $7.25 to $7.75 per share in cash, which represents a 59%-70% premium to Wednesday's closing price, and adopted a shareholder rights plan to avert a hostile takeover attempt. Shareholder Capital, which owns 200,000 outstanding shares of Vanda, asked in its letter, "on what basis did the Board reject Future Pak's offer, which values Vanda shares at nearly 2x their unaffected price."

  • Associated Press Finance

    Chinese ship remains prime suspect in damage to Baltic Sea gas pipeline that reopened this week

    A Chinese container ship remains the prime suspect in causing damage last year to a Baltic Sea gas pipeline between NATO members Finland and Estonia, Finnish investigators said Thursday. It has been over six months since substantial, human-made damage that caused a major drop in pressure was first detected in the Balticconnector pipeline in Finnish economic waters on Oct. 8. Finland and Estonia's gas system operators were forced to shut it down, disconnecting a crucial link between the Nordic and Baltic gas markets for several months.

  • GlobeNewswire

    Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

    HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2). Mark White, CEO of Nexalin, stated, “We remain committed to our mission of revolutionizing the treatment of mental health and neurological condi